×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SVRA – savara, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SVRA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
11/22
08:11 am
svra
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 [Yahoo
Medium
Report
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 [Yahoo
11/22
08:05 am
svra
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Medium
Report
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
11/13
10:08 am
svra
Savara Inc (NASDAQ: SVRA) had its price target lowered by analysts at HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Savara Inc (NASDAQ: SVRA) had its price target lowered by analysts at HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
11/13
08:20 am
svra
Savara Announces Participation in Upcoming Healthcare Conferences [Yahoo! Finance]
High
Report
Savara Announces Participation in Upcoming Healthcare Conferences [Yahoo! Finance]
11/13
08:05 am
svra
Savara Inc (NASDAQ: SVRA) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $5.00 price target on the stock, down previously from $7.00.
High
Report
Savara Inc (NASDAQ: SVRA) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $5.00 price target on the stock, down previously from $7.00.
11/13
08:05 am
svra
Savara Announces Participation in Upcoming Healthcare Conferences
High
Report
Savara Announces Participation in Upcoming Healthcare Conferences
11/12
08:05 am
svra
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
10/1
10:05 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-3.3%
10/1
10:05 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-3.3%
Date
Time
Symbol
Headline
Impact
11/20
07:56 am
svra
Form 4 Savara Inc For: Nov 19 Filed by: McCracken Joseph S
Medium
Report
Form 4 Savara Inc For: Nov 19 Filed by: McCracken Joseph S
11/18
12:33 pm
svra
Form 4 Savara Inc For: Nov 18 Filed by: RAMSAY DAVID A
Low
Report
Form 4 Savara Inc For: Nov 18 Filed by: RAMSAY DAVID A
11/14
05:49 pm
svra
Form SC 13G/A Savara Inc Filed by: PRUDENTIAL FINANCIAL INC
Medium
Report
Form SC 13G/A Savara Inc Filed by: PRUDENTIAL FINANCIAL INC
11/12
05:18 pm
svra
Form 4 Savara Inc For: Nov 10 Filed by: Pratt Raymond Dennis
High
Report
Form 4 Savara Inc For: Nov 10 Filed by: Pratt Raymond Dennis
11/12
04:01 pm
svra
Form 10-Q Savara Inc For: Sep 30
High
Report
Form 10-Q Savara Inc For: Sep 30
11/12
10:25 am
svra
Form SC 13G/A Savara Inc Filed by: JENNISON ASSOCIATES LLC
Medium
Report
Form SC 13G/A Savara Inc Filed by: JENNISON ASSOCIATES LLC
11/12
09:38 am
svra
Form SC 13G/A Savara Inc Filed by: Adage Capital Management, L.P.
Medium
Report
Form SC 13G/A Savara Inc Filed by: Adage Capital Management, L.P.
11/8
02:18 pm
svra
Form SC 13G Savara Inc Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Savara Inc Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/30
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
180.6%
11/15 Form 8-K Savara Inc For: Nov 15 21.1%
11/27 Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 18.9%
12/20 Form 8-K Savara Inc For: Dec 20 15.1%
6/28 Form 4 Savara Inc For: Jun 26 Filed by: RAMSAY DAVID A 13.9%
12/20 Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million 10.4%
3/25 Statement Of Support By The PAP Foundation, Inc. For FDA Approval Of GM-CSF Treatment For aPAP 8.2%
10/31 Savara to Report Third Quarter 2019 Financial Results and Provide Business Update 7.3%
3/17 Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 6.3%
4/9 Form SC 13G/A Savara Inc Filed by: BlackRock Inc. 6.1%
11/15 Form 8-K Savara Inc For: Nov 15 21.1%
11/27 Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 18.9%
12/20 Form 8-K Savara Inc For: Dec 20 15.1%
6/28 Form 4 Savara Inc For: Jun 26 Filed by: RAMSAY DAVID A 13.9%
12/20 Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million 10.4%
3/25 Statement Of Support By The PAP Foundation, Inc. For FDA Approval Of GM-CSF Treatment For aPAP 8.2%
10/31 Savara to Report Third Quarter 2019 Financial Results and Provide Business Update 7.3%
3/17 Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 6.3%
4/9 Form SC 13G/A Savara Inc Filed by: BlackRock Inc. 6.1%
TOP News Decliners
10/2
Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
-58.5%
3/17 Form 4 Savara Inc For: Mar 10 Filed by: Sun Ricky -19.4%
2/3 Form 8-K Savara Inc For: Jan 31 -15.8%
4/2 Form 8-K Savara Inc For: Mar 31 -14.3%
12/30 Form SC 13D Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P. -12.8%
3/12 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus -0.310 ActVsEst (0.410) - Miss -9.8%
3/30 Savara Provides Business Update in Response to COVID-19 Pandemic -9.8%
12/3 Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors -8.4%
8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.430 ActVsEst (0.140) - Miss -8.4%
6/13 Savara Inc (NASDAQ: SVRA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.2%
3/17 Form 4 Savara Inc For: Mar 10 Filed by: Sun Ricky -19.4%
2/3 Form 8-K Savara Inc For: Jan 31 -15.8%
4/2 Form 8-K Savara Inc For: Mar 31 -14.3%
12/30 Form SC 13D Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P. -12.8%
3/12 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus -0.310 ActVsEst (0.410) - Miss -9.8%
3/30 Savara Provides Business Update in Response to COVID-19 Pandemic -9.8%
12/3 Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors -8.4%
8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.430 ActVsEst (0.140) - Miss -8.4%
6/13 Savara Inc (NASDAQ: SVRA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: